LANSING, Michigan — Food and animal safety products company Neogen Corp. has acquired a United Kingdom-based business that sells 50 test kits for food allergens.
A statement from Neogen didn’t include the price of the deal for BioKits, a subsidiary of San Diego-based Gen-Probe Inc., but the Lansing State Journal reported it at $6.5 million.
BioKits employs 25 people in Deeside, Wales and is expected to record sales of $3 million this year.
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
“This acquisition provides a good opportunity for Neogen since the markets and products are both synergistic to our continued growth,” said James Herbert, the company’s chief executive, according to a statement from Neogen.
The acquired company will operate as part of Neogen’s Scotland-based European subsidiary.
As concerns about food safety grow, Neogen could be well-positioned to take advantage of a growing market with its test kits. Last month, Neogen’s board approved a 3-for-2 stock split in which shareholders as of Nov. 3o would receive an additional share for every two shares they own.
Earlier this week, TheStreet.com included Neogen in a list of five “fast-growing stocks set to gain.” The website noted that Neogen’s stock has risen 30 percent this year, outpacing the S&P 500 and the Dow Jones Industrial Average. TheStreet said Neogen is in “an ideal financial position” with $24 million in cash and no debt on its balance sheet.
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Neogen reported revenue of $32 million in its most recent quarter, the 70th of the past 75 quarters in which the company has reported year-over-year revenue growth, according to the company.